Hoth Therapeutics' GDNF Shows Superior Liver Fat Reprogramming in Preclinical Study

Event summary

  • Hoth Therapeutics reported positive HT-VA study data showing GDNF reprograms liver fat metabolism at the genetic level in a MAFLD model.
  • GDNF significantly reduced Srebf1 (fat production gene) and increased Pparα (fat metabolism gene) more effectively than semaglutide.
  • Study conducted under CRADA with U.S. Department of Veterans Affairs and Emory University.
  • Results position GDNF as potential first-in-class therapy targeting root causes of fatty liver disease and obesity.

The big picture

Hoth's positive GDNF data represents a strategic pivot into high-value metabolic indications beyond its core dermatology and oncology pipeline. The results suggest a potential first-in-class approach to metabolic reprogramming, which could position the company as a competitor to existing weight-loss focused therapies. The metabolic disease market, including MAFLD and obesity, represents a significant expansion opportunity for Hoth's clinical-stage portfolio.

What we're watching

Clinical Translation
Whether preclinical gene expression results will translate to clinical efficacy in human MAFLD patients.
Competitive Positioning
How Hoth will differentiate GDNF against established GLP-1 agonists in the obesity and metabolic disease market.
Development Pathway
The pace at which Hoth advances GDNF through additional preclinical validation and potential clinical trials.